FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose

INSYS Therapeutics, Inc. (OTCMKTS: INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing. INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8mg naloxone dose.
Stock Symbols

Hot Stock: Insys Therapeuti, Shares Gain 35.6% (INSY)

Insys Therapeuti (NASDAQ:INSY) is one of today’s best performing penny stocks, up 35.6% to $0.46 on 2.6x average daily volume. Insys Therapeuti has traded 8.1 million shares thus far today, vs. average volume of 3.1 million shares per day. The stock has outperformed the Dow (35.6% to the Dow’s 0.3%) and outperformed the S&P 500 (35.6% to the S&P’s 0.3%) during today’s trading.
Stock Symbols

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions related to the Chapter 11 petitions filed on June 10, 2019.
Stock Symbols

Stock to Watch: Insys Therapeuti Down 69.7% (INSY)

Insys Therapeuti (NASDAQ:INSY) is one of today’s worst performing low-priced stocks, down 69.7% to $1.09 on 1.5x average daily volume. Thus far today, Insys Therapeuti has traded 631,000 shares, vs. average volume of 412,000 shares per day. The stock has underperformed the Dow (-69.7% to the Dow’s -1.1%) and underperformed the S&P 500 (-69.7% to the S&P’s -1.1%) during today’s trading.
Stock Symbols

INSYS Therapeutics Implements Leadership Changes

INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company.
Stock Symbols

INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting

INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel naloxone nasal spray versus intravenous and intramuscular injection at the College on Problems of Drug Dependence (CPDD)’s 81st Annual Scientific Meeting in San Antonio, Texas on Monday, June 17, 2019 at 8:00am Central Time.
Stock Symbols

INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results

INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for its fourth quarter and full year ended Dec. 31, 2018.
Stock Symbols

INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7

INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, Mar. 7, after the U.S. financial markets close.
Stock Symbols